It is generally accepted that tumour cells gain a selective advantage by deregulation of the cell cycle as a consequence of oncogene activation and tumour-suppressor gene inactivation (Weinberg, 1989; Hunter, 1991) . There is also growing support for the idea that tumour cells may have defective mechanisms of programmed cell death (Wyllie, 1993) . In addition, it has been suggested that the limited lifespan of normal human cells (Hayflick, 1965) may act as a mechanism of tumour suppression (Sager, 1989) and that breakdown of this limited lifespan to yield immortal variants could be a rate-limiting step in carcinogenesis (Newbold et al., 1982; Newbold and Overell, 1983) .
Until recently support for these ideas was hampered by the lack of molecular mechanisms of limited lifespan that were distinct from those of cell cycle regulation. In the last 5 years evidence has now accumulated to show that at every round of cell division human chromosomes lose a certain amount of DNA at the telomere that that this may be the basis of the limited replicative lifespan of normal cells (Harley et al., 1990) . Furthermore, in order to escape this limit, 85% of human cancers reactivate the enzyme telomerase to halt telomeric attrition and become immortal (Counter et al., 1994a; Kim et al., 1994) . Also it is possible that many tumour cells are dependent on telomerase for their continued replication and survival (Feng et al., 1995) and this, coupled with its tumour specificity, makes telomerase an attractive target for cancer therapy (Harley et al., 1990) .
The role of telomeric attrition in replicative senescence has been the subject of several excellent commentaries recently (de Lange 1994; Kipling, 1995; Wynford-Thomas et al., 1995) and will be discussed only briefly here. The main purpose of this article is to review the current knowledge on telomeric attrition and telomerase activation in human cancer and assess the potential value of anti-telomerases in cancer treatment.
The telomere theory of limited proliferative lifespan Telomeres are structures consisting of repeat sequences of DNA and telomere-associated proteins that cap human chromosomes (see Zakian, 1989; Greider, 1990; Blackburn, 1991 for recent reviews). At the telomere the DNA replication machinery leaves a gap at the 5' end of the lagging strand, which, if it is not filled, results in the progressive shortening of the chromosomes, a phenomenon known as the end replication problem (Watson, 1972) . Following the cloning of human telomeres, two groups showed that the telomeres of fibroblasts in vitro and tissues in vivo shortened with both replicative lifespan in vitro (Harley et al., 1990) and donor age in vivo (Harley et al., 1990; Hastie et al., 1990) . It has since been shown that many human cells and tissues display the phenomenon of telomeric attrition, including haemopoietic stem cells (Vaziri et al., 1994) (Benn, 1976) , 1992; Mantell and Greider, 1994) because of the activity of the enzyme, telomerase, originally discovered in the ciliate Tetrahymena (Greider and Blackburn, 1985) . This enzyme solves the end replication problem by filling in the 5' gap in a highly controlled way so that normally telomere length is sustained at each cell division, not significantly lengthened or shortened. Telomerase is a ribonucleoprotein; it is composed of an RNA primer encoded by a single gene (Feng et al., 1995) (Counter et al., 1992 (Counter et al., , 1994b and in immortal human tumour cells (Morin, 1989; Counter et al., 1994a; Kim et al., 1994; Nilsson et al., 1994; Hiyama et al., 1995) . More importantly, the enzyme activity is detectable in over 80% of human tumour samples in vivo, including most of the common and therapeutically intractable types (Counter et al., 1994a; Nilsson et al., 1994; Kim et al., 1994; Hiyama et al., 1995) . Furthermore, in neuroblastoma, the level of the enzyme correlated strongly with genetic instability and clinical outcome (Hiyama et al., 1995), the enzyme being absent in three samples of stage IVS neuroblastoma that spontaneously regressed.
Despite the strong correlation between telomerase reactivation, cellular immortalisation and cancer, the critical experiment was the recent demonstration that inhibition of human telomerase limits the lifespan of immortal human tumour cells with critically short telomeres (Feng et al., 1995) . Therefore, telomerase reactivation appears to be causal in the process of human cellular immortalisation and cancer progression, not merely consequential (Kipling, 1995) . In addition, since telomerase is not significantly regulated throughout the cell cycle (Mantell and Greider, 1994) these results support the notion that normally limited lifespan presents an independent barrier to tumour progression (Newbold et al., 1982; Newbold and Overell, 1983; Sager, 1989) which is distinct from cell cycle control (Weinberg, 1989; Hunter, 1991) . One might also predict that some tumour-suppressor genes may turn out to be suppressors of telomerase activity (Sager, 1989) and preliminary evidence suggests that such a gene may map to chromosome 3 (see Seachrist, 1995 Herlyn, 1989; Paraskeva et al., 1988; Counter et al., 1994a; Kim et al., 1994; Edington et al., 1995) , telomerase antagonists may be useful when traditional methods of cancer therapy, generally most effective against early stage cancer, have failed. Thus, anti-telomerases promise a novel, and for the first time tumour-specific, approach to cancer therapy that might also be effective against advanced and disseminated tumours.
In arguing against the value of anti-telomerase therapy Kipling (1995) pointed out that the phenotypic lag caused by 20 population doublings would allow a marble-sized tumour to grow to the size of a small family car. Firstly, this is an unrealistic estimate based on the behaviour of in vitro cell populations and in vivo only a small proportion of most solid tumours actually divides. Secondly, it is very likely that the number of human tumour cell divisions is not matched by an equivalent increase in tumour mass; even in advanced tumours many cells continue to terminally differentiate and many tumour cells are continually lost through apoptosis (Wyllie, 1993) or attack from the host defences (Esteban et al., 1990; Wolf et al., 1990) . Finally, even if the argument of phenotypic lag turns out to be true, it would still be possible to use telomerase antagonists to prevent recurrence once conventional therapy has reduced the tumour burden to several thousand cells (Goldie and Coldman, 1979) . It is nevertheless true that many human tumours and some immortal cell lines have very long telomeres regardless of the level of telomerase activity (Kim et al., 1994; Hiyama et al., 1995) . The significance of these observations is still unclear (Kipling, 1995) and may suggest that at least some tumours may not respond to anti-telomerases.
Possible mechanisms of resistance to telomerase antagonists Telomerase-negative tumours with long telomeres may have arisen from a tissue or target cell, e.g. a germ cell (Wynford- Thomas et al., 1995) or somatic stem cell, which originally possessed a longer than average telomere and consequently enough proliferative power to generate an advanced tumour without cellular immortalisation. Alternatively these tumours may have solved the end replication problem by a mechanism that does not involve telomerase, and recombinational mechanisms of dealing with telomeric attrition are known from studies of Saccharomyces (Wang and Zakian 1990; Lundblad and Blackburn, 1993) and Drosophila (Biessman et al., 1990; Levis et al., 1993) . Some advanced tumours are mortal (Edington et al., 1995) and these tumours may account for the 15% of advanced human tumours that are telomerase negative (Kim et al., 1994 ), but it is also possible that recombinational mechanisms of telomere healing are at work in telomerase-positive cells such as HeLa (Morin, 1989) and human keratinocytes transformed by human papillomavirus (Klingelhutz et al., 1994) , both of which show evidence of telomere healing. It is difficult to see how selection for telomerase activation could take place unless at least some of the tumour cells have at some stage possessed critically short telomeres (Counter et al., 1992) . However, since cells with shorter telomeres may have a selective advantage under certain circumstances (Larson et al., 1987) , it is still possible that some tumour cells in some telomerasepositive tumours may have long telomeres, especially as the telomerase TRAP assay is capable of detecting just one positive cell in one thousand (Kim et al., 1994; Kipling, 1995) . Lastly, in the case of both telomerase-positive and -negative tumours the apparent appearance of long telomeres, as assessed by Southern blotting, could be misleading. The presence of large numbers of contaminating normal cells, or cells with many dicentric chromosomes, may lead to the spurious detection of long telomeres and even tumour cells that have long telomeres on average may have at least one telomere that is critically short (de Lange, 1994) . These technical problems could be resolved if reliable in situ methods of quantitating telomere length are developed and applied.
Clearly, one mechanism of resistance to anti-telomerases relates to the argument that not enough tumour cells have a critically short telomere for the drug to eliminate the turnover rapidly enough (Kipling, 1995) and this has been discussed above. There is a definite need to understand what a critical telomere length is at the level of the individual cell and how it leads to cell death during crisis (Counter et al., 1992) , as well as understanding how telomere length changes throughout tumour progression and following cancer therapy. In addition, even tumours with critically short telomeres and active telomerase may become resistant to anti-telomerases, perhaps by abrogating signalling from the shortened telomere to the cell cycle or the apoptosis mechanisms. Finally, it is still a possibility that telomerase antagonists, like many other drugs, may become therapeutically inactive as a result of resistance mechanisms that prevent sufficient drug reaching telomerase. For instance, resistance to many anti-cancer drugs can be caused by increased efflux of a drug from the cell (Gottesman, 1993) . It is also possible that in large tumours with poor blood supplies the drugs may have difficult reaching the target cells, but if non-toxic specific anti-telomerases can be designed this and other conventional therapeutic problems should be lessened.
The lack of similarity of the telomerase protein components to other known polymerases (Collins et al., 1995) encourages the belief that anti-telomerases of high specificity could be designed. Despite the fact that such drugs are presently a possibility rather than a reality and the potential problems detailed in this article, telomerase is an enzyme that has considerable potential for cancer therapy. The challenge now is to investigate some of the issues raised above so that this potential may one day be realised.
